Free Trial

Ironwood Pharmaceuticals Q3 2023 Earnings Report

Ironwood Pharmaceuticals logo
$4.45 +0.57 (+14.69%)
(As of 12/20/2024 05:40 PM ET)

Ironwood Pharmaceuticals Earnings Headlines

Ironwood Pharma (IRWD) Receives a Buy from Craig-Hallum
Ironwood Pharmaceuticals shares surge on competitor's woes
Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
3 Penny Stocks to Watch for Big Gains in 2025
See More Ironwood Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ironwood Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ironwood Pharmaceuticals and other key companies, straight to your email.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ:IRWD), a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

View Ironwood Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings